CDKN2A and cancer: Notably, patients with HPVDNA+/p16+ TSCC/BOTSCC had a clearly better OS and DFS than those with HPVDNA−/p16− TSCC/BOTSCC, both in the uni- and in the multivariate analysis, while those with HPVDNA−/p16+ TSCC/BOTSCC only had a significantly better OS compared to those with HPVDNA−/p16− cancer in the univariate analysis (Table 2).